Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 18/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841578 | 0.83 | CCNT1 (0.59) | PDPK1NTRK1 | |
| SCHEMBL2640128 | 0.80 | PDPK1 (0.65) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL14001685 | 0.80 | PDPK1 (0.78) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL2429160 | 0.79 | PDPK1 (0.60) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456782 | 0.79 | PDPK1 (0.61) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1604109 | 0.78 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL13541693 | 0.78 | PDPK1 (0.74) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1604236 | 0.77 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL2421437 | 0.76 | PDPK1 (0.56) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1456024 | 0.76 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | claimed |
| JP-2011526260-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2291375-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010000364-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-01-07 | — | — | WO | claimed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2291375-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010000364-A1 | PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MKI67, CCNT1, CCNI | PDPK1 429/4885PIK3CA 2075/4885PIK3CG 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.